Exiqon Expects Initial Data from Blood-Based Colon Cancer Dx in Early 2010 | GenomeWeb

Exiqon this week said it expects initial results from a Danish National Technology Foundation-funded effort to develop a microRNA-based blood diagnostic for colon cancer in the first quarter of 2010.

The disclosure came as part of the company’s announcement of its financial results for the first half of 2009, which included a roughly 32 percent rise in revenues and a 28 percent jump in net losses.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.